Premium
Comparative drug elimination capacity in man‐glutethimide, amobarbital, antipyrine, and sulfinpyrazone
Author(s) -
Kadar D.,
Inaba T.,
Endrenyi L.,
Johnson G. E.,
Kalow W.
Publication year - 1973
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1973144part1552
Subject(s) - glutethimide , amobarbital , sulfinpyrazone , chemistry , secobarbital , medicine , pharmacology , epilepsy , platelet , pentobarbital , psychiatry
The apparent elimination half‐lifes were determined for 4 drugs that undergo hydroxylation in men. Glutethimide (500 mg), amobarbital sodium (130 mg), antipyrine (1.0 gm), and sulfinpyrazone (400 mg) were each taken orally by 10 healthy men at weekly intervals. When the half‐lifes in these 10 individuals were compared, positive correlations were found among 3 out of 4 drugs: glutethimide‐amobarbital (r 0.69, p < 0.05), glutethimide‐sulfinpyrazone (r 0.64, p < 0.05), and amobarbital‐sulfinpyrazone (r 0.87, p < 0.01). If these data are generally valid, it would mean, for example, that one could, from the sulfinpyrazone half‐life in a given subject, predict the amobarbital half‐life of the same individual within about ± 7 hours (30% of average half‐life, while the interindividual differences could be 300%). Antipyrine half‐life was not correlated with the half‐life of any of the other 3 drugs. The urinary levels of 6β‐hydroxycortisol were also determined in the same sub;ects and compared with the half‐lifes of the 4 drugs. The correlation coefficients taken singly were not statistically significant, but they were all negative and collectively seem to indicate an expected trend.